Jaclyn Tamaroff1, Anna DeDio2, Kristin Wade2, McKenzie Wells3, Courtney Park3, Karla Leavens4, Christian Rummey5, Andrea Kelly4, David R Lynch6, Shana E McCormack4. 1. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. Electronic address: jaclyn.tamaroff@vumc.org. 2. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. 3. Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA. 4. Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. 5. Clinical Data Science GmbH, Basel, Switzerland. 6. Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
AIMS: Friedreich's Ataxia (FRDA) is a progressive neuromuscular disorder typically caused by GAA triplet repeat expansions in both frataxin gene alleles. FRDA can be complicated by diabetes mellitus (DM). The objective of this study was to describe the prevalence of, risk factors for, and management practices of FRDA-related DM. METHODS: FACOMS, a prospective, multi-site natural history study, includes 1,104 individuals. Extracted data included the presence of DM and other co-morbidities, genetic diagnosis, and markers of disease severity. We performed detailed medical record review and a survey for the subset of individuals with FRDA-related DM followed at one FACOMS site, Children's Hospital of Philadelphia. RESULTS: FRDA-related DM was reported by 8.7% of individuals. Age, severe disease, and FRDA cardiac complications were positively associated with DM risk. FRDA-related DM was generally well-controlled, as reflected by HbA1c, though diabetic ketoacidosis did occur. Insulin is the mainstay of treatment (64-74% overall); in adults, metformin use was common and newer glucose-lowering agents were used rarely. CONCLUSIONS: Clinical factors identify individuals at increased risk for FRDA-related DM. Future studies should test strategies for FRDA-related DM screening and management, in particular the potential role for novel glucose-lowering therapies in preventing or delaying FRDA-related cardiac disease.
AIMS: Friedreich's Ataxia (FRDA) is a progressive neuromuscular disorder typically caused by GAA triplet repeat expansions in both frataxin gene alleles. FRDA can be complicated by diabetes mellitus (DM). The objective of this study was to describe the prevalence of, risk factors for, and management practices of FRDA-related DM. METHODS: FACOMS, a prospective, multi-site natural history study, includes 1,104 individuals. Extracted data included the presence of DM and other co-morbidities, genetic diagnosis, and markers of disease severity. We performed detailed medical record review and a survey for the subset of individuals with FRDA-related DM followed at one FACOMS site, Children's Hospital of Philadelphia. RESULTS: FRDA-related DM was reported by 8.7% of individuals. Age, severe disease, and FRDA cardiac complications were positively associated with DM risk. FRDA-related DM was generally well-controlled, as reflected by HbA1c, though diabetic ketoacidosis did occur. Insulin is the mainstay of treatment (64-74% overall); in adults, metformin use was common and newer glucose-lowering agents were used rarely. CONCLUSIONS: Clinical factors identify individuals at increased risk for FRDA-related DM. Future studies should test strategies for FRDA-related DM screening and management, in particular the potential role for novel glucose-lowering therapies in preventing or delaying FRDA-related cardiac disease.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Amy Y Tsou; Erin K Paulsen; Sarah J Lagedrost; Susan L Perlman; Katherine D Mathews; George R Wilmot; Bernard Ravina; Arnulf H Koeppen; David R Lynch Journal: J Neurol Sci Date: 2011-06-08 Impact factor: 3.181
Authors: Sean R Regner; Nicholas S Wilcox; Lisa S Friedman; Lauren A Seyer; Kim A Schadt; Karlla W Brigatti; Susan Perlman; Martin Delatycki; George R Wilmot; Christopher M Gomez; Khalaf O Bushara; Katherine D Mathews; S H Subramony; Tetsuo Ashizawa; Bernard Ravina; Alicia Brocht; Jennifer M Farmer; David R Lynch Journal: J Child Neurol Date: 2012-06-29 Impact factor: 1.987
Authors: Angeliki Pappa; Martin G Häusler; Andreas Veigel; Konstantina Tzamouranis; Martin W Pfeifer; Andreas Schmidt; Martin Bökamp; Holger Haberland; Siegfried Wagner; Joachim Brückel; Gideon de Sousa; Lukas Hackl; Esther Bollow; Reinhard W Holl Journal: Diabetes Res Clin Pract Date: 2018-05-26 Impact factor: 5.602
Authors: M Cossée; A Dürr; M Schmitt; N Dahl; P Trouillas; P Allinson; M Kostrzewa; A Nivelon-Chevallier; K H Gustavson; A Kohlschütter; U Müller; J L Mandel; A Brice; M Koenig; F Cavalcanti; A Tammaro; G De Michele; A Filla; S Cocozza; M Labuda; L Montermini; J Poirier; M Pandolfo Journal: Ann Neurol Date: 1999-02 Impact factor: 10.422
Authors: Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch Journal: Diabetes Care Date: 2015-06-15 Impact factor: 19.112
Authors: Nicholas G Fox; Xiaodi Yu; Xidong Feng; Henry J Bailey; Alain Martelli; Joseph F Nabhan; Claire Strain-Damerell; Christine Bulawa; Wyatt W Yue; Seungil Han Journal: Nat Commun Date: 2019-05-17 Impact factor: 14.919
Authors: Christian Rummey; Louise A Corben; Martin Delatycki; George Wilmot; Sub H Subramony; Manuela Corti; Khalaf Bushara; Antoine Duquette; Christopher Gomez; J Chad Hoyle; Richard Roxburgh; Lauren Seeberger; Grace Yoon; Katherine Mathews; Theresa Zesiewicz; Susan Perlman; David R Lynch Journal: Neurology Date: 2022-07-11 Impact factor: 11.800